Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been given an average rating of “Moderate Buy” by the nineteen analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, thirteen have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $38.4706.

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, October 8th. Raymond James Financial reissued a “strong-buy” rating and issued a $40.00 price target on shares of Dyne Therapeutics in a research note on Monday, December 8th. Evercore ISI reduced their price objective on shares of Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, December 15th. Oppenheimer upgraded shares of Dyne Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $11.00 to $40.00 in a report on Wednesday, December 10th. Finally, Sanford C. Bernstein set a $23.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, December 9th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. CWM LLC raised its position in Dyne Therapeutics by 168.1% during the second quarter. CWM LLC now owns 3,030 shares of the company’s stock valued at $29,000 after buying an additional 1,900 shares during the period. Chung Wu Investment Group LLC acquired a new stake in shares of Dyne Therapeutics during the third quarter worth approximately $30,000. Mirae Asset Global Investments Co. Ltd. grew its position in Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after purchasing an additional 1,109 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after buying an additional 955 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after buying an additional 7,697 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Down 5.8%

DYN stock opened at $18.26 on Friday. The firm has a market cap of $2.61 billion, a PE ratio of -4.99 and a beta of 1.32. Dyne Therapeutics has a 12 month low of $6.36 and a 12 month high of $25.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.47 and a quick ratio of 13.47. The firm has a 50 day simple moving average of $19.99 and a 200 day simple moving average of $15.13.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.05. Equities research analysts forecast that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.